Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: A nationwide study

Europace

Volumn 11, Issue 7, 2009, Pages 886-891

  Andersen, Søren Skøtt ^a   Hansen, Morten Lock ^a   Gislason, Gunnar H ^b   Schramm, Tina Ken ^a   Folke, Fredrik ^a   Fosbøl, Emil ^a   Abildstrøm, Steen Z ^c   Madsen, Mette ^d   Køber, Lars ^b   Torp Pedersen, Christian ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Antiarrhythmic drug therapy; Atrial fibrillation

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; PROPAFENONE; SOTALOL; WARFARIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DRUG SAFETY; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; COHORT STUDIES; DENMARK; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 67650901953     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eup119     Document Type: Article

References (20)

1. Ruskin JN. The cardiac arrhythmia suppression trial (CAST). N Engl J Med 1989; 321:386-8.
2. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with Oral d-Sotalol. Lancet 1996;348:7-12.
3. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
4. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
5. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358:2667-77.
6. Hansen ML, Gadsboll N, Gislason GH, Abildstrom SZ, Schramm TK, Folke F et al. Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers. Europace 2008;10:395-402.
7. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993;270:1589-95.
8. Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med 1994;331: 785-91.
9. Heidenreich PA, Keeffe B, McDonald KM, Hlatky MA. Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death. Am Heart J 2002;144:422-30.
10. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003;56:124-30.
11. Rasmussen S, Zwisler AD, Abildstrom SZ, Madsen JK, Madsen M. Hospital variation in mortality after first acute myocardial infarction in Denmark from 1995 to 2002: lower short-term and 1-year mortality in high-volume and specialized hospitals. Med Care 2005;43:970-8.
12. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991;133:144- 53.
13. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/ AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association the Heart Rhythm Society. Europace 2006;8:651-745.
14. Nichol G, McAlister F, Pham B, Laupacis A, Shea B, Green M et al. Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart 2002;87:535-43.
15. Steinberg JS, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004;109:1973-80.
16. Kaufman ES, Zimmermann PA, Wang T, Dennish GW 3rd, Barrell PD, Chandler ML et al. Risk of proarrhythmic events in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study: a multivariate analysis. J Am Coll Cardiol 2004;44:1276-82.
17. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87.
18. Hirschl DA, Jain VR, Spindola-Franco H, Gross JN, Haramati LB. Prevalence and characterization of asymptomatic pacemaker and ICD lead perforation on CT. Pacing Clin Electrophysiol 2007;30:28-32.
19. Ramirez MF, Ching CK, Ho KL, Teo WS. "The attack of the 52 cm lead": an unusual case of late cardiac perforation by a passive-fixation permanent pacemaker lead. IntJ Cardiol 2007;115:e5-7.
20. Selcuk H, Selcuk Mt, Maden OT, Ozeke O, Celenk MK, Turkvatan A et al. Uncomplicated heart and lung perforation by a displaced ventricular pacemaker lead: a case report. Pacing Clin Electrophysiol 2006;29:429-30.